Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jul 29

PMID 37511193

Authors

Shamar Young

Jack Hannallah

Dan Goldberg

Tina Sanghvi

Junaid Arshad

Aaron Scott

Gregory Woodhead

Affiliations

Soon will be listed here.

Abstract

Over the last several decades, a number of new treatment options for patients with hepatocellular carcinoma (HCC) have been developed. While treatment decisions for some patients remain clear cut, a large numbers of patients have multiple treatment options, and it can be hard for multidisciplinary teams to come to unanimous decisions on which treatment strategy or sequence of treatments is best. This article reviews the available data with regard to two treatment strategies, immunotherapies and locoregional therapies, with a focus on the potential of locoregional therapies to be combined with checkpoint inhibitors to improve outcomes in patients with locally advanced HCC. In this review, the available data on the immunomodulatory effects of locoregional therapies is discussed along with available clinical data on outcomes when the two strategies are combined.

Citing Articles

Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study.

Guo C, Du W, Chen Y, Xiao W, Sun K, Shen Y Cancer Med. 2025; 14(3):e70633.

PMID: 39907261 PMC: 11795419. DOI: 10.1002/cam4.70633.

Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions.

Young S, Hannallah J, Goldberg D, Khreiss M, Shroff R, Arshad J Semin Intervent Radiol. 2024; 40(6):515-523.

PMID: 38274222 PMC: 10807971. DOI: 10.1055/s-0043-1777711.

Thermal Ablation in the Liver: Heat versus Cold-What Is the Role of Cryoablation?.

DSouza D, Ragulojan R, Guo C, Dale C, Jones C, Talaie R Semin Intervent Radiol. 2024; 40(6):491-496.

PMID: 38274220 PMC: 10807970. DOI: 10.1055/s-0043-1777845.

Advances in Molecular Medicine: Unravelling Disease Complexity and Pioneering Precision Healthcare.

Bustin S, Jellinger K Int J Mol Sci. 2023; 24(18).

PMID: 37762471 PMC: 10531697. DOI: 10.3390/ijms241814168.

References

de la Torre-Alaez M, Matilla A, Varela M, Inarrairaegui M, Reig M, Lledo J . Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J Immunother Cancer. 2022; 10(11). PMC: 9716796. DOI: 10.1136/jitc-2022-005457. View

Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, De Baere T . Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2020; 6(1):17-29. DOI: 10.1016/S2468-1253(20)30290-9. View

Hannon G, Lesch M, Gerber S . Harnessing the Immunological Effects of Radiation to Improve Immunotherapies in Cancer. Int J Mol Sci. 2023; 24(8). PMC: 10138513. DOI: 10.3390/ijms24087359. View

Su T, Wu C, Liu T, Ho C, Liu C . Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective. Clin Mol Hepatol. 2023; 29(2):230-241. PMC: 10121301. DOI: 10.3350/cmh.2022.0421. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Mehta A, Oklu R, Sheth R . Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?. Gastroenterol Res Pract. 2016; 2016:9251375. PMC: 4802022. DOI: 10.1155/2016/9251375. View

Chen X, Lai L, Ye J, Li L . Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:740762. PMC: 8639517. DOI: 10.3389/fonc.2021.740762. View

Yau T, Park J, Finn R, Cheng A, Mathurin P, Edeline J . Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2021; 23(1):77-90. DOI: 10.1016/S1470-2045(21)00604-5. View

Shao Q, OFlanagan S, Lam T, Roy P, Pelaez F, Burbach B . Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. Int J Hyperthermia. 2019; 36(1):130-138. DOI: 10.1080/02656736.2018.1539253. View

10.

Sabel M, Nehs M, Su G, Lowler K, Ferrara J, Chang A . Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. 2005; 90(1):97-104. DOI: 10.1007/s10549-004-3289-1. View

11.

Huigsloot M, Tijdens I, Mulder G, van de Water B . Differential regulation of phosphatidylserine externalization and DNA fragmentation by caspases in anticancer drug-induced apoptosis of rat mammary adenocarcinoma MTLn3 cells. Biochem Pharmacol. 2001; 62(8):1087-97. DOI: 10.1016/s0006-2952(01)00755-9. View

12.

Zaitoun M, Elsayed S, Zaitoun N, Soliman R, Elmokadem A, Farag A . Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3-<5 cm. Int J Hyperthermia. 2021; 38(1):248-256. DOI: 10.1080/02656736.2021.1887941. View

13.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

14.

Reynders K, Illidge T, Siva S, Chang J, De Ruysscher D . The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015; 41(6):503-10. PMC: 4816218. DOI: 10.1016/j.ctrv.2015.03.011. View

15.

El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492-2502. PMC: 7539326. DOI: 10.1016/S0140-6736(17)31046-2. View

16.

Feng K, Yan J, Li X, Xia F, Ma K, Wang S . A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012; 57(4):794-802. DOI: 10.1016/j.jhep.2012.05.007. View

17.

Wissniowski T, Hansler J, Neureiter D, Frieser M, Schaber S, Esslinger B . Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res. 2003; 63(19):6496-500. View

18.

Dromi S, Walsh M, Herby S, Traughber B, Xie J, Sharma K . Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology. 2009; 251(1):58-66. PMC: 2663580. DOI: 10.1148/radiol.2511072175. View

19.

Widenmeyer M, Shebzukhov Y, Haen S, Schmidt D, Clasen S, Boss A . Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer. 2010; 128(11):2653-62. DOI: 10.1002/ijc.25601. View

20.

Seidensticker M, Powerski M, Seidensticker R, Damm R, Mohnike K, Garlipp B . Cytokines and Y-Radioembolization: Relation to Liver Function and Overall Survival. Cardiovasc Intervent Radiol. 2017; 40(8):1185-1195. DOI: 10.1007/s00270-017-1622-4. View